^
    25d
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1, N=174, Completed, Boehringer Ingelheim | Phase classification: P1a/1b --> P1
    Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    BI 894999
    8ms
    Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours. (PubMed, Eur J Cancer)
    The 1.5, 2.5, and 6.0/3.0 mg doses in Schedules A, B, and C, respectively, were declared as maximum tolerated dose. Based on the strength of these data, BI 894999 was further evaluated in a Phase Ib trial.
    P1 data • Journal • Metastases
    |
    BI 894999
    2years
    Pancreatic clonal replica tumors display functional heterogeneity in response to KRAS pharmacological inhibition and reveal unique epigenetic vulnerabilities to overcome resistance (AACR 2022)
    Our study suggests that pre-existing heterogeneous subclones with epigenetic plasticity contribute to escaping direct KRAS inhibition in pancreatic cancer and provides a new avenue to overcome such resistance by combining KRAS inhibitors with BET inhibitors.
    Late-breaking abstract
    |
    KRAS (KRAS proto-oncogene GTPase) • BRD3 (Bromodomain Containing 3)
    |
    KRAS mutation • KRAS G12C • KRAS G12D
    |
    Mekinist (trametinib) • MRTX1133 • BI-3406 • BI 894999
    over2years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=174, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EGFR (Epidermal growth factor receptor)
    |
    BI 894999
    almost3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=174, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor)
    |
    BI 894999
    almost3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=204, Recruiting, Boehringer Ingelheim | Trial completion date: Aug 2022 --> Dec 2021 | Trial primary completion date: Jul 2022 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    BI 894999
    almost3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=204, Recruiting, Boehringer Ingelheim | Trial primary completion date: Apr 2018 --> Jul 2022
    Clinical • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    BI 894999
    4years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=176, Recruiting, Boehringer Ingelheim | Trial completion date: May 2021 --> May 2022
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    BI 894999